Immunex Message Board - Msg: 16375098

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (573)	9/18/2001 6:38:45 PM
From: LemurHouse	of 656

Thanks for posting that story. IMNX is currently conducting a PhII study for using Enbrel to treat ankylosing spondylitis -- the malady mentioned in the article -- and is expected to report data this quarter or next, with Ph III trials expected to begin in Q1 of 2002. Other indications being investigated are for Wegener's Granulomatosis, for which Ph II and III trials are currently underway. A second, larger Ph II trial is being initiated for Psoriasis, following positive results from initial small Ph II. Correction to my earlier post: psoriatic arthritis req was submitted in mid-July, not June. AD

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next